WAVE Life Sciences Ltd at Goldman Sachs Healthcare Conference Transcript
Welcome to the inaugural session of the 47 Annual Goldman Sachs Healthcare Research Conference. Pleased to be joined by Wave Life Sciences, and Paul. So first, Paul, for those in audience and listening, who may be less familiar with Wave today specifically, what do you think is the most important thing for investors to understand about the company and where it stands today?
Well, thanks for having us. And it's a great time to be connecting as we kind of hit the midpoint of 2026. We're kind of at, what I would call, a strategic inflection point on operating against what we set out as a strategy as we began 2026, which is: one, we see our platform chemistry translating into potentially meaningful therapies, starting with WVE-007 for Inhibin E coming off of our initial clinical data seeing again in the siRNA space, our chemistry uniquely translate to a meaningful improvement in body composition in a Phase 1 healthy volunteer study and excited for the updates as we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
